Want to see TSE:PCLO full AI Analyst Report?
PharmaCielo (PCLO) AI Stock Analysis
PharmaCielo
(TSXV:PCLO)
The overall score is low primarily because the company’s financial position is very weak, with persistent large losses, a highly stretched balance sheet, and significant ongoing cash burn that require continued access to external capital. Technical indicators provide only modest support, showing a neutral to slightly negative trading pattern without strong positive momentum, while valuation metrics are constrained by a negative P/E and lack of dividend, offering little fundamental downside protection and underscoring the high-risk, turnaround nature of the stock.
PharmaCielo (PCLO) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 7.83M
- Dividend Yield
- ―
- Average Volume (3M)
- 86.13K
- Price to Earnings (P/E)
- -2.7
- Beta (1Y)
- -3.50
- Revenue Growth
- 0.90%
- EPS Growth
- 57.73%
- Country
- Canada
- Employees
- 268
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
PharmaCielo Business Overview & Revenue Model
Company Description
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medici...
How the Company Makes Money
PharmaCielo’s primary revenue model is business-to-business (B2B) sales of cannabis-derived ingredients and related products. The company seeks to monetize its operations by (1) cultivating and/or sourcing cannabis biomass and converting it into proc...
PharmaCielo Financial Statement Overview
Summary
Financial performance is very weak overall: despite recent revenue growth and a recovery in gross margins to the mid-30s, the company continues to post large operating and net losses, has a highly leveraged and fragile balance sheet with negative equity, and sustains substantial negative operating and free cash flow, leaving it dependent on external funding.
Income Statement
32NegativeBalance Sheet
14Very NegativeCash Flow
21Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.60M | 2.61M | 3.48M | 1.54M | 5.31M | 1.94M |
| Gross Profit | 1.34M | 756.40K | 730.88K | -1.37M | 827.06K | -4.31M |
| EBITDA | -317.50K | -1.00M | -4.60M | -12.19M | -10.50M | -24.34M |
| Net Income | -3.71M | -4.55M | -9.14M | -16.30M | -16.04M | -26.92M |
Balance Sheet | ||||||
| Total Assets | 12.75M | 8.56M | 18.39M | 22.29M | 25.12M | 35.96M |
| Cash, Cash Equivalents and Short-Term Investments | 77.50K | 289.24K | 147.94K | 62.18K | 325.98K | 5.63M |
| Total Debt | 18.21M | 18.65M | 20.52M | 18.31M | 12.59M | 8.43M |
| Total Liabilities | 23.44M | 23.92M | 25.91M | 23.97M | 18.72M | 16.63M |
| Stockholders Equity | -10.70M | -15.35M | -7.52M | -1.68M | 6.39M | 19.33M |
Cash Flow | ||||||
| Free Cash Flow | -6.96M | -1.02M | -1.97M | -5.17M | -10.23M | -21.21M |
| Operating Cash Flow | -6.96M | -1.02M | -1.97M | -5.15M | -9.71M | -20.07M |
| Investing Cash Flow | 10.05M | 6.66M | 41.14K | 391.64K | -725.49K | -1.66M |
| Financing Cash Flow | -3.04M | -5.52M | 2.02M | 4.63M | 5.30M | 18.21M |
PharmaCielo Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PCLO, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 43.32 is Neutral, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PCLO.
PharmaCielo Peers Comparison
Overall Rating
TSE:LABS49Neutral
TSE:INNO44Neutral
TSE:OILS43Neutral- TSE:PCLO43Neutral
TSE:ATLE42Neutral
TSE:AVCN41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:LABS | 49Neutral | CAD 27.77M | -5.17 | -13.79% | ― | -6.74% | 43.54% |
| TSE:INNO | 44Neutral | CAD 8.55M | -6.54 | -19.37% | ― | -19.20% | 42.54% |
| TSE:OILS | 43Neutral | CAD 3.40M | -1.31 | -43.92% | ― | -18.30% | -397.37% |
| TSE:PCLO | 43Neutral | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% |
| TSE:ATLE | 42Neutral | CAD 41.96M | -0.76 | -2099.75% | ― | -100.00% | 94.43% |
| TSE:AVCN | 41Neutral | CAD 14.11M | -3.09 | -108.44% | ― | -0.23% | -142.54% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:PCLO | Pharmacielo | 0.05 | 0.01 | 11.11% | |
| TSE:ATLE | Willow Biosciences | 0.09 | -0.09 | -50.00% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.06 | -0.01 | -14.29% | |
| TSE:OILS | Nextleaf Solutions | 0.01 | -0.04 | -75.00% | |
| TSE:AVCN | Avicanna Inc | 0.10 | -0.14 | -59.18% | |
| TSE:INNO | Innocan Pharma Corporation | 1.90 | -16.10 | -89.44% |
PharmaCielo Corporate Events
PharmaCielo Revenue Surges on European Cannabis Sales as It Preserves Cash with Share-Based Interest Payment
PositivePharmaCielo reported a sharp rebound in its 2026 first quarter, with revenue rising to $1.4 million from $0.3 million a year earlier, driven by a broader geographic footprint and new dried flower sales into Europe. The company swung to a gross profit...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 06, 2026